G Stein

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer treatment and survivorship statistics, 2022

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States

The multitude and diversity of environmental carcinogens

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Cell cycle proteins as promising targets in cancer therapy

Lifestyle-related factors and environmental agents causing cancer: An overview

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Plasmonic photothermal therapy (PPTT) using gold nanoparticles

Non-Hodgkin lymphoma

Strategies and challenges for the next generation of antibody–drug conjugates

Development of therapeutic antibodies for the treatment of diseases

3D printing based on imaging data: review of medical applications

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Chimeric antigen receptor T-cell therapies for lymphoma

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

Monoclonal antibodies in myeloma.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis

Cancer therapy with ultrasound: A historical review

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Rapid prototyping techniques for anatomical modelling in medicine.

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

Polymers for 3D Printing and Customized Additive Manufacturing

Genetic toxicity of some important epoxides

Chimeric Antigen Receptor Therapy

Cancer treatment and survivorship statistics, 2016

Impact of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS

Vinyl chloride: still a cause for concern.

Cancer treatment and survivorship statistics, 2019

Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Ferroptosis as a target for protection against cardiomyopathy

Industrial mutagens and potential mutagens I. Halogenated aliphatic derivatives

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

Parellel inhibition of LH-RH-induced cyclic AMP accumulation and LH and FSH release by LH-RH antagonists in vitro.

Three-dimensional ultrasonography in maxillofacial surgery. A new diagnostic tool

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

[RESULTS OF COMBINED ROENTGEN AND ULTRASONIC THERAPY OF MALIGNANT SKIN TUMORS].

Die sogenannte Vinylchlorid-Krankheit?eine berufsbedingte Systemsklerose?

[Vinyl chloride disease (author's transl)].